The clinical-stage biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced its financial results for the first half of 2025 and shared updates on its clinical and corporate progress.
Between December 2024 and July 2025, the company secured €52 million in funding, including €30 million from a capital increase, €13,2 million from an EU-IPCEI grant, and €1,8 million from R&D cash-back incentives. Also, Oryzon terminated its financing agreement with Nice & Green, increasing its treasury stock as part of the settlement.
Clinical development continues to progress. In neuroscience, the Phase III PORTICO-2 trial protocol for vafidemstat in borderline personality disorder (BPD) has been submitted to the FDA. The EVOLUTION Phase IIb trial in schizophrenia is expanding across the EU, and preparations are underway for a new Phase II trial targeting aggression in autism spectrum disorder. Oryzon has also strengthened its IP portfolio, receiving new patent grants related to the treatment of behavioural alterations.
In oncology, the iadademstat program is advancing across several indications, including relapsed/refractory and first-line acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), and small cell lung cancer (SCLC). Moreover, the company is expanding iadademstat’s clinical application into non-malignant haematological disorders, with a Phase Ib trial in sickle cell disease (SCD) submitted for EMA approval.
Financially, the company reported R&D expenses of $5,8 million and a net loss of $3,4 million for the first half of 2025, consistent with expectations for a company in clinical development. As of June 30, 2025, Oryzon had $36,5 million in cash and equivalents, positioning it well to advance its strategic initiatives.
Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Our successful €30 million capital raise, executed under extraordinarily challenging market conditions, represents a strong vote of confidence in Oryzon’s science, clinical pipeline, and long-term value proposition. The proceeds not only reinforce our financial position but also elevate our visibility in the international biotech arena. This funding enables us to advance our clinical programs with renewed momentum and strategic clarity. We are confident that the clinical progress and data to be presented in the coming quarters will further validate the trust placed in us by the investment community.”
Comments